Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD for Preventing Oxaliplatin-Induced Neuropathy in Colorectal Cancer
NCT07167446Phase 1Recruiting
- Sponsor
- Fox Chase Cancer Center
- Start
- Oct 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial comparing Cannabidiol (CBD) with Standard of Care (2 arms). Primary endpoints: Proportion of participants adherent to the CBD supplementation protocol at 12 weeks and Acceptability of CBD supplementation at 12 weeks. Started Oct 2025; status: recruiting.
02
Drugs
cannabidiol
Beyond the preview
Go deeper on NCT07167446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07167446.